Perivascular Epithelioid Cell Neoplasms - 25 Studies Found
Recruiting |
: A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa : PEComa : 2015-07-08 : Drug: ABI-009 |
Withdrawn |
: A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa : Malignant PEComa (Perivascular Epithelioid Cell Tumors) : 2012-09-06 : Drug: BEZ235 Patients will be provided with an adequate supply of study treatment for self-administratio |
Completed |
: Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors :
: 2014-12-22 : Other: Biopsy |
Not yet recruiting |
: Trabectedin Maintenance Post 1st-line in STS : Sarcoma, Soft Tissue : 2016-10-07 : Drug: Trabectedin Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 |
Recruiting |
: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery :
|
Recruiting |
: Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus : Sporadic Angiomyolipomas (AMLs) : 2015-08-20 : Drug: Everolimus 10 mg tablets |
Recruiting |
: Sirolimus in Treating Patients With Angiomyolipoma of the Kidney : Nonmalignant Neoplasm : 2005-08-02 : Drug: sirolimus |
Not yet recruiting |
: LAM Pilot Study With Imatinib Mesylate : Lymphangioleiomyomatosis : 2017-04-24 :
|
Recruiting |
: A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) : Lymphangioleiomyomatosis : 2016-10-07 : Drug: Nintedanib Other Name: OFEV |
Recruiting |
: Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis : Pulmonary Lymphangioleiomyomatosis : 2016-03-31 : Drug: saracatinib Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject wi |